Back to top
more

Allogene Therapeutics (ALLO)

(Real Time Quote from BATS)

$2.62 USD

2.62
132,585

-0.05 (-1.87%)

Updated Oct 2, 2024 10:47 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Apellis (APLS) Stock Up 50% in Three Months: Here's Why?

by Zacks Equity Research

Apellis (APLS) stock rises 50% in the past three months owing to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake in its first marketed product, Empaveli, also contributed to the surge.

Here's Why Allogene Therapeutics (ALLO) is Poised for a Turnaround After Losing -17.44% in 4 Weeks

by Zacks Equity Research

The heavy selling pressure might have exhausted for Allogene Therapeutics (ALLO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals

by Zacks Equity Research

Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.

Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod

by Zacks Equity Research

Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.

Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee

by Zacks Equity Research

Roche (RHHBY) gets majority votes from the FDA's Advisory Committee for Polivy combination for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).

BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be in focus.

Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.

Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate

by Zacks Equity Research

Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.

Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up

by Zacks Equity Research

Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news.

Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review

by Zacks Equity Research

Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA

Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept

by Zacks Equity Research

Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.

Allogene Therapeutics (ALLO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Allogene Therapeutics (ALLO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus

by Zacks Equity Research

Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6.

Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl

by Zacks Equity Research

Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.

After Plunging -23.01% in 4 Weeks, Here's Why the Trend Might Reverse for Allogene Therapeutics (ALLO)

by Zacks Equity Research

Allogene Therapeutics (ALLO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top

by Zacks Equity Research

Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.

Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.

Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales

by Zacks Equity Research

Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.

Horizon's (HZNP) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) reports better-than-expected fourth-quarter 2022 results as it beats the Zacks Consensus Estimate for both revenues and earnings.

Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues beat estimates.

Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil

by Zacks Equity Research

Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.

Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.

Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Allogene's (ALLO) fourth-quarter earnings beat estimates but sales come in line.

Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down

by Zacks Equity Research

Novavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with earnings and revenues both missing the Zacks Consensus Estimate. Stock plunges 26.1% in response to the news.